Search
mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease.
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency,
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalIt should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).
Pancrelipase protease
go.drugbank.com/drugs/DB11066ApprovedInvestigational[A32742, L2543] The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510] … [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigational[L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in
Vorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalIt is the first in a new class of agents known as histone deacetylase inhibitors. … A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnIt was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults. … Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedThey include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. … Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Methoxamine
go.drugbank.com/drugs/DB00723ApprovedInvestigationalWithdrawnAn alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.
Metixene
go.drugbank.com/drugs/DB00340ApprovedMetixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.